Morris Dylan R, Ayabe Kengo, Inoue Takashi, Sakai Nobuyuki, Bulbulia Richard, Halliday Alison, Goto Shinya
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford.
J Atheroscler Thromb. 2017 Apr 3;24(4):373-387. doi: 10.5551/jat.38745. Epub 2017 Mar 4.
Carotid artery stenosis is responsible for between 10-20% of all ischaemic strokes. Interventions, such as carotid endarterectomy and carotid stenting, effectively reduce the risk of stroke in selected individuals. This review describes the history of carotid interventions, and summarises reliable evidence on the safety and efficacy of these interventions gained from large randomised clinical trials.Early trials comparing carotid endarterectomy to medical therapy alone in symptomatic patients, and asymptomatic patients, demonstrated that endarterectomy halved the risk of stroke and perioperative death in these two unique populations. The absolute risk reduction was smaller in the asymptomatic carotid trials, consistent with their lower absolute stroke risk. More recent trials in symptomatic patients, suggest that carotid stenting has similar long term durability to carotid endarterectomy, but possibly has higher procedural hazards dominated by non-disabling strokes. The Asymptomatic Carotid Surgery Trial-2, along with individual patient data meta-analysis of all asymptomatic trials, will provide reliable evidence for the choice of intervention in asymptomatic patients in whom a decision has been made for carotid revascularisation. Given improvements in effective cardiovascular medical therapy, in particular lipid-lowering medications, there is renewed uncertainty as to whether carotid interventions still provide meaningful net reductions in stroke risk in asymptomatic populations. Four large trials in Europe and the US are currently underway, and are expected to report long-term results in the next decade.It is essential that surgeons, interventionalists, and physicians continue to randomise large numbers of patients from around the world to clarify current uncertainty around the management of asymptomatic carotid stenosis.
在所有缺血性卒中中,10%-20%由颈动脉狭窄所致。颈动脉内膜切除术和颈动脉支架置入术等干预措施可有效降低特定个体的卒中风险。本综述描述了颈动脉干预的历史,并总结了从大型随机临床试验中获得的关于这些干预措施安全性和有效性的可靠证据。早期对有症状患者和无症状患者进行的比较颈动脉内膜切除术与单纯药物治疗的试验表明,内膜切除术使这两类独特人群的卒中和围手术期死亡风险减半。在无症状颈动脉试验中,绝对风险降低幅度较小,这与其较低的绝对卒中风险一致。近期针对有症状患者的试验表明,颈动脉支架置入术与颈动脉内膜切除术具有相似的长期疗效,但可能具有以非致残性卒中为主的更高手术风险。无症状颈动脉手术试验-2以及对所有无症状试验的个体患者数据荟萃分析,将为已决定进行颈动脉血运重建的无症状患者的干预选择提供可靠证据。鉴于有效的心血管药物治疗,特别是降脂药物的改进,对于颈动脉干预是否仍能在无症状人群中显著降低卒中风险,再次出现了不确定性。目前欧洲和美国正在进行四项大型试验,预计将在未来十年报告长期结果。外科医生、介入专家和内科医生必须继续对来自世界各地的大量患者进行随机分组,以澄清目前无症状颈动脉狭窄管理方面的不确定性。